AU1674400A - Kidney disease detection and treatment - Google Patents

Kidney disease detection and treatment

Info

Publication number
AU1674400A
AU1674400A AU16744/00A AU1674400A AU1674400A AU 1674400 A AU1674400 A AU 1674400A AU 16744/00 A AU16744/00 A AU 16744/00A AU 1674400 A AU1674400 A AU 1674400A AU 1674400 A AU1674400 A AU 1674400A
Authority
AU
Australia
Prior art keywords
treatment
kidney disease
disease
disease detection
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16744/00A
Other languages
English (en)
Inventor
Wayne D. Comper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monash University
Original Assignee
Monash University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP7843A external-priority patent/AUPP784398A0/en
Application filed by Monash University filed Critical Monash University
Publication of AU1674400A publication Critical patent/AU1674400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
AU16744/00A 1998-12-21 1999-12-20 Kidney disease detection and treatment Abandoned AU1674400A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPP7843 1998-12-21
AUPP7843A AUPP784398A0 (en) 1998-12-21 1998-12-21 Kidney disease detection and treatment
US09/415,217 US6447989B1 (en) 1998-12-21 1999-10-12 Kidney disease detection and treatment
US09415217 1999-10-12
PCT/IB1999/002029 WO2000037944A1 (en) 1998-12-21 1999-12-20 Kidney disease detection and treatment

Publications (1)

Publication Number Publication Date
AU1674400A true AU1674400A (en) 2000-07-12

Family

ID=25645955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16744/00A Abandoned AU1674400A (en) 1998-12-21 1999-12-20 Kidney disease detection and treatment

Country Status (13)

Country Link
US (3) US20020012906A1 (enExample)
EP (1) EP1141728B1 (enExample)
JP (2) JP4160263B2 (enExample)
CN (1) CN1331801A (enExample)
AT (1) ATE376187T1 (enExample)
AU (1) AU1674400A (enExample)
BR (1) BR9916407A (enExample)
CA (1) CA2356174A1 (enExample)
DE (1) DE69937368T2 (enExample)
DK (1) DK1141728T3 (enExample)
IL (1) IL143892A0 (enExample)
MX (1) MXPA01006404A (enExample)
WO (1) WO2000037944A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP784398A0 (en) 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
AU1674400A (en) 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
AU2002305159B2 (en) * 2001-03-28 2007-12-13 Heska Corporation Methods of detecting early renal disease in animals
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
CN100556546C (zh) * 2003-02-13 2009-11-04 贝克顿·迪金森公司 在血液收集过程中去除成分的装置及其使用
US7482128B2 (en) 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
JP2007521232A (ja) 2003-08-08 2007-08-02 アブジェニックス・インコーポレーテッド 副甲状腺ホルモン（ｐｔｈ）に対する抗体およびその使用
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
JP5785355B2 (ja) * 2004-11-24 2015-09-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における生体異物物質の肝臓クリアランスを改良する方法
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
US8647660B2 (en) * 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
CN102907561A (zh) * 2004-12-30 2013-02-06 希尔氏宠物营养品公司 提高老年动物的生活质量的方法
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
EP1874130A4 (en) * 2005-04-19 2009-04-29 Hills Pet Nutrition Inc METHOD AND COMPOSITIONS FOR PREVENTING AND TREATING NURSE DISEASES
CA2605855A1 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
CA2608670C (en) * 2005-05-20 2019-03-05 Hill's Pet Nutrition, Inc. Methods for promoting health or wellness in adult animals
WO2007002836A2 (en) * 2005-06-29 2007-01-04 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
CA2619042C (en) * 2005-08-17 2011-03-15 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
AU2008223791B2 (en) * 2007-03-07 2013-10-03 Mosaiques Diagnostics And Therapeutics Ag Method for the standardization of the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
EP2535718B1 (en) * 2007-05-11 2014-07-09 The Institutes for Pharmaceutical Discovery, LLC Methods for early diagnosis of kidney disease
AU2008309605A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide marker for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
JP2011515672A (ja) * 2008-03-19 2011-05-19 モザイクス ダイアグノスティクス アンド セラピューティクス アーゲー 腎尿細管の損傷および疾患の診断のための方法およびマーカー
EP2313778B1 (en) * 2008-07-18 2015-01-28 Boston Medical Center Corporation Diagnostics for membranous nephropathy
NZ610356A (en) * 2008-08-28 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9057735B2 (en) * 2008-08-29 2015-06-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2338054A1 (de) * 2008-09-17 2011-06-29 Mosaiques Diagnostics And Therapeutics AG Nierenzellkarzinom
CN104020284B (zh) * 2008-10-21 2016-08-24 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
NZ628843A (en) * 2008-10-21 2016-02-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2528799T3 (es) * 2008-11-22 2015-02-12 Astute Medical, Inc. Métodos para el pronóstico de insuficiencia renal aguda
WO2010064239A1 (en) 2008-12-04 2010-06-10 Technion Research And Development Foundation Ltd. Apparatus and methods for diagnosing renal disorders
BRPI1007483B1 (pt) * 2009-01-28 2021-11-30 Bio Preventive Medicine Corporation Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5827226B2 (ja) * 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
CN102792161B (zh) * 2009-08-28 2014-11-12 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后的方法及组合物
EA201290192A1 (ru) 2009-11-07 2013-02-28 Астьют Медикал, Инк. Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
MX2012005210A (es) * 2009-11-07 2012-08-03 Astute Medical Inc Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
DK2666872T3 (en) 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
EP2539712A4 (en) 2010-02-26 2013-09-18 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2011162821A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20130203074A1 (en) 2010-06-23 2013-08-08 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012019110A1 (en) * 2010-08-05 2012-02-09 Abbott Laboratories Method and system for managing patient healthcare
DE102010038014B4 (de) * 2010-10-06 2021-10-07 Numares Ag Verwendung spezifischer Substanzen als Marker zur Bestimmung des Risikos einer Nierenabstoßung
KR101215759B1 (ko) 2010-11-01 2012-12-26 서울대학교산학협력단 오로소뮤코이드를 포함하는 조성물의 용도
PT2691530T (pt) 2011-06-10 2018-05-10 Univ Oregon Health & Science Glicoproteínas e vectores recombinantes cmv
CN102854325B (zh) * 2011-07-01 2015-01-07 复旦大学 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US20130115640A1 (en) * 2011-11-03 2013-05-09 James A. Tumlin ACTH for Treatment of Kidney Disease
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9689826B2 (en) 2012-03-11 2017-06-27 Technion Research And Development Foundation Ltd. Detection of chronic kidney disease and disease progression
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2016188761A (ja) * 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
CN104007258B (zh) * 2013-09-30 2016-07-06 中国医学科学院基础医学研究所 局灶性节段性肾小球硬化的蛋白标志物
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
CN105917229B (zh) 2013-12-03 2019-04-26 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断和预后的方法和组合物
CN104849466A (zh) * 2014-02-14 2015-08-19 张曼 尿液玻璃体结合蛋白在2型糖尿病合并早期肾损伤诊治中的应用
US20170205427A1 (en) * 2014-07-23 2017-07-20 University Of British Columbia Biomarkers for anderson-fabry disease
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016164854A1 (en) 2015-04-09 2016-10-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CN107561175A (zh) * 2017-08-10 2018-01-09 武汉大学 一种肾小球硬化大鼠模型的评价方法
RU2697722C1 (ru) * 2018-12-06 2019-08-19 Ирина Сергеевна Шатохина Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
CN110632229A (zh) * 2019-09-24 2019-12-31 华兰生物工程重庆有限公司 高效液相色谱仪检测静注人免疫球蛋白(pH4)蛋白质含量的方法
CN111714517A (zh) * 2020-04-14 2020-09-29 南开大学 一种溶酶体作为制备药物领域的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994165A (en) * 1989-02-16 1991-02-19 Cornell Research Foundation, Inc. Liquid junction coupling for capillary zone electrophoresis/ion spray spectrometry
DE69221666T2 (de) 1991-05-24 1998-01-15 Wakamoto Pharma Co Ltd Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten
JPH0682446A (ja) * 1992-08-31 1994-03-22 Wakamoto Pharmaceut Co Ltd 腎疾患の診断法
DE4336498A1 (de) * 1993-10-26 1995-04-27 Bender & Co Gmbh Verfahren zur Diagnose von Nieren- und Gefäßerkrankungen
US5534431A (en) 1994-02-28 1996-07-09 The Board Of Regents Of The University Of Nebraska Hybridomas and monoclonal antibodies specific for unique determinants of nephropathy-related immunoglobulin G and complexes thereof
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5800998A (en) * 1996-11-12 1998-09-01 Millennium Pharmaceuticals, Inc. Assays for diagnosing type II diabetes in a subject
AU1674400A (en) 1998-12-21 2000-07-12 Monash University Kidney disease detection and treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768464C1 (ru) * 2021-04-27 2022-03-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ диагностики мембранозной нефропатии как одной из форм хронического гломерулонефрита

Also Published As

Publication number Publication date
JP2006038877A (ja) 2006-02-09
EP1141728B1 (en) 2007-10-17
US20020022236A1 (en) 2002-02-21
JP2002533680A (ja) 2002-10-08
CA2356174A1 (en) 2000-06-29
BR9916407A (pt) 2001-09-25
IL143892A0 (en) 2002-04-21
JP4160263B2 (ja) 2008-10-01
DE69937368T2 (de) 2008-07-17
US20020012906A1 (en) 2002-01-31
EP1141728A4 (en) 2005-01-12
DK1141728T3 (da) 2008-02-04
ATE376187T1 (de) 2007-11-15
US20040106155A1 (en) 2004-06-03
WO2000037944A1 (en) 2000-06-29
EP1141728A1 (en) 2001-10-10
DE69937368D1 (de) 2007-11-29
JP4388515B2 (ja) 2009-12-24
US6589748B2 (en) 2003-07-08
MXPA01006404A (es) 2003-06-06
CN1331801A (zh) 2002-01-16

Similar Documents

Publication Publication Date Title
AU1674400A (en) Kidney disease detection and treatment
AU4040097A (en) Signal amplification method
WO1999058978A3 (en) Tumour markers
DE69530861D1 (de) Vorrichtung zur durchführung eines oder mehrerer kompetitiver immunoassays
EP1634966A3 (en) Methods for detection of nucleic acid sequences in urine
NZ306051A (en) Testing using electrochemiluminescence
AU7686094A (en) Method, reagent and kit for the detection of fecal occult blood
AU1671300A (en) Cancer detection method and reagents
CA2214488A1 (en) Determination of cpsa
EP0836096A3 (en) A method of diagnosing and monitoring colorectal cancer
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
EP0653637A3 (en) Dry elements, test devices and kits and methods for chemiluminescent detection of analytes using reagents marked with peroxidase.
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
AU2707597A (en) Method of assay
CA2407760A1 (en) Methods for diagnosis of low grade astrocytoma
EP0723156A3 (en) Assay normalization method
EP0387027A3 (en) Endometriosis diagnosis methods and reagents
CA2213083A1 (en) Detection of antibody production
EP0940681A3 (en) Method and device for the detection of an analyte in a fluid test sample
CA2346406A1 (en) Detection of pleiotrophin
IL100527A (en) Prescreening of prostate cancer by serum prostatic specific antigen
ES8707798A1 (es) Un procedimiento para analizar una muestra de tejido para determinar la presencia de antigeno de la hepatitis no a no b
WO1999027366A3 (en) Method of detecting prostate specific antigen activation peptide
AU3441997A (en) Determination of analytes by means of two markers
WO2001086292A3 (en) Ipg assay

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase